Compare PRPL & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRPL | ENTX |
|---|---|---|
| Founded | 2010 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.9M | 62.6M |
| IPO Year | 2015 | 2015 |
| Metric | PRPL | ENTX |
|---|---|---|
| Price | $0.64 | $1.16 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $0.85 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 283.1K | 175.6K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 152.75 | N/A |
| EPS | ★ 0.48 | 0.25 |
| Revenue | ★ $468,725,000.00 | $42,000.00 |
| Revenue This Year | $10.83 | N/A |
| Revenue Next Year | $6.81 | N/A |
| P/E Ratio | ★ $1.25 | $4.72 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.57 | $0.91 |
| 52 Week High | $1.26 | $3.22 |
| Indicator | PRPL | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 45.72 | 48.33 |
| Support Level | $0.57 | $1.17 |
| Resistance Level | $0.73 | $1.61 |
| Average True Range (ATR) | 0.04 | 0.13 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 24.24 | 56.25 |
Purple Innovation Inc is a comfort innovation company. The company designs, manufactures and sells a range of comfort technology offerings, including mattresses, a pillow, cushions, sheets, bed platforms and other products. The Company has one reportable segment that operates an omni-channel distribution which allows the Company to offer a seamless shopping experience to its customers across multiple sales channels. It sells its products through its direct-to-consumer e-commerce channels, retail brick-and-mortar wholesale partners, Purple showrooms, and third-party online retailers.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.